Results with CCNU in resistant Hodgkin's and non-Hodgkin's lymphoma.
Results with CCNU in resistant Hodgkin's and non-Hodgkin's lymphoma.
复制标题
CCNU 在耐药霍奇金淋巴瘤和非霍奇金淋巴瘤中的结果。
作者：
D. Stolinsky;J. Solomon;J. Weiner;J. Bateman
72例标准化疗无效的晚期恶性淋巴瘤患者口服1-（2-氯乙基）-3-环己基亚硝基脲（CCNU）130 mg/m2，每6周1次。39例可评价的霍奇金病患者中有13例出现客观缓解，15例淋巴细胞性淋巴瘤患者中有3例出现客观缓解，7例组织细胞性淋巴瘤患者中有1例出现客观缓解。缓解持续1至22个月（中位数：4个月），发生在对烷化剂、长春碱、长春新碱、皮质类固醇、甲基苄肼和博莱霉素耐药的患者中。白细胞减少和血小板减少是治疗的常见毒性反应。
72 patients with advanced malignant lymphoma resistant to standard chemotherapy were treated with 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (CCNU) at 130 mg/m2 orally every six weeks. Objective responses were noted in 13 of 39 evaluable patients with Hodgkin's disease, three of 15 patients with lymphocytic lymphoma, and one of seven patients with histiocytic lymphoma. Responses lasted one to 22 months (median: four months) and occurred in patients whose disease was resistant to alkylating agents, vinblastine, vincristine, corticosteroids, procarbazine, and bleomycin. Leukopenia and thrombocytopenia were frequent toxic effects of therapy.